202 related articles for article (PubMed ID: 18234225)
1. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.
Barinka C; Hlouchova K; Rovenska M; Majer P; Dauter M; Hin N; Ko YS; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Mol Biol; 2008 Mar; 376(5):1438-50. PubMed ID: 18234225
[TBL] [Abstract][Full Text] [Related]
2. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.
Novakova Z; Cerny J; Choy CJ; Nedrow JR; Choi JK; Lubkowski J; Berkman CE; Barinka C
FEBS J; 2016 Jan; 283(1):130-43. PubMed ID: 26460595
[TBL] [Abstract][Full Text] [Related]
3. Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
Mlcochová P; Plechanovová A; Barinka C; Mahadevan D; Saldanha JW; Rulísek L; Konvalinka J
FEBS J; 2007 Sep; 274(18):4731-41. PubMed ID: 17714508
[TBL] [Abstract][Full Text] [Related]
4. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.
Barinka C; Byun Y; Dusich CL; Banerjee SR; Chen Y; Castanares M; Kozikowski AP; Mease RC; Pomper MG; Lubkowski J
J Med Chem; 2008 Dec; 51(24):7737-43. PubMed ID: 19053759
[TBL] [Abstract][Full Text] [Related]
5. Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity.
Plechanovová A; Byun Y; Alquicer G; Skultétyová L; Mlčochová P; Němcová A; Kim HJ; Navrátil M; Mease R; Lubkowski J; Pomper M; Konvalinka J; Rulíšek L; Bařinka C
J Med Chem; 2011 Nov; 54(21):7535-46. PubMed ID: 21923190
[TBL] [Abstract][Full Text] [Related]
6. Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II.
Navrátil M; Ptáček J; Šácha P; Starková J; Lubkowski J; Bařinka C; Konvalinka J
FEBS J; 2014 Jul; 281(14):3228-42. PubMed ID: 24863754
[TBL] [Abstract][Full Text] [Related]
7. Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods.
Klusák V; Barinka C; Plechanovová A; Mlcochová P; Konvalinka J; Rulísek L; Lubkowski J
Biochemistry; 2009 May; 48(19):4126-38. PubMed ID: 19301871
[TBL] [Abstract][Full Text] [Related]
8. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.
Barinka C; Rovenská M; Mlcochová P; Hlouchová K; Plechanovová A; Majer P; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Med Chem; 2007 Jul; 50(14):3267-73. PubMed ID: 17567119
[TBL] [Abstract][Full Text] [Related]
9. Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III.
Hlouchova K; Barinka C; Konvalinka J; Lubkowski J
FEBS J; 2009 Aug; 276(16):4448-62. PubMed ID: 19678840
[TBL] [Abstract][Full Text] [Related]
10. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Mesters JR; Barinka C; Li W; Tsukamoto T; Majer P; Slusher BS; Konvalinka J; Hilgenfeld R
EMBO J; 2006 Mar; 25(6):1375-84. PubMed ID: 16467855
[TBL] [Abstract][Full Text] [Related]
11. S1 pocket of glutamate carboxypeptidase II: a new binding site for amyloid-β degradation.
Lee SK; Kim H; Cheong YH; Kim MJ; Jo SA; Youn HS; Park SI
Biochem Biophys Res Commun; 2013 Sep; 438(4):765-71. PubMed ID: 23891752
[TBL] [Abstract][Full Text] [Related]
12. Glutamate carboxypeptidase II does not process amyloid-β peptide.
Sedlák F; Šácha P; Blechová M; Březinová A; Šafařík M; Šebestík J; Konvalinka J
FASEB J; 2013 Jul; 27(7):2626-32. PubMed ID: 23525279
[TBL] [Abstract][Full Text] [Related]
13. A high-resolution structure of ligand-free human glutamate carboxypeptidase II.
Barinka C; Starkova J; Konvalinka J; Lubkowski J
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Mar; 63(Pt 3):150-3. PubMed ID: 17329803
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II.
Pavlicek J; Ptacek J; Cerny J; Byun Y; Skultetyova L; Pomper MG; Lubkowski J; Barinka C
Bioorg Med Chem Lett; 2014 May; 24(10):2340-5. PubMed ID: 24731280
[TBL] [Abstract][Full Text] [Related]
15. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA.
Mesters JR; Henning K; Hilgenfeld R
Acta Crystallogr D Biol Crystallogr; 2007 Apr; 63(Pt 4):508-13. PubMed ID: 17372356
[TBL] [Abstract][Full Text] [Related]
16. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Barinka C; Sácha P; Sklenár J; Man P; Bezouska K; Slusher BS; Konvalinka J
Protein Sci; 2004 Jun; 13(6):1627-35. PubMed ID: 15152093
[TBL] [Abstract][Full Text] [Related]
17. Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Navrátil M; Tykvart J; Schimer J; Pachl P; Navrátil V; Rokob TA; Hlouchová K; Rulíšek L; Konvalinka J
FEBS J; 2016 Jul; 283(13):2528-45. PubMed ID: 27208881
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors.
Rong SB; Zhang J; Neale JH; Wroblewski JT; Wang S; Kozikowski AP
J Med Chem; 2002 Sep; 45(19):4140-52. PubMed ID: 12213057
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
20. Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme.
Pavlícek J; Ptácek J; Barinka C
Curr Med Chem; 2012; 19(9):1300-9. PubMed ID: 22304708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]